Previous research studies

Currently recruiting


Have you had Bacterial Vaginosis (BV) in the past? Do you have BV now?
Would you be willing to take part in a study to enable better treatment of BV in the future?
Do you have access to the internet to complete online questionnaires?

For more information please contact the research team and speak to Marion Campbell – 01273 523079
…just say you would like more information on the VITA study


The Unit has been conducting studies for over 20 years and has experience in the following areas:
• National & international studies
• Locally generated research
• Collaboration with the Medical Research Council (MRC), the Pharmaceutical Industry and other units across the UK and abroad

Examples of the types of studies we conduct include:
• Studies on new antiretroviral drugs
• Studies to explore different treatment strategies e.g. simplifying HIV treatment
• The management of treatment side effects and management of other medical conditions e.g. HIV and Heart, Kidney/Liver
• Studies where we observe the effect of HIV on people over time and
• The screening and treatment for Sexually Transmitted Infections (STIs)
• HIV prevention and transmission studies





0111 – Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
0112 – Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
0109 – Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
1089 – Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
1844 (Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF )
1489 (Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine )
1878 (Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide )
0109 (Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination)
0122 (Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection)
2055 (DISCOVER PrEP study)















START – Strategic Timing of AntiRetroviral Treatment





047 – A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
056 – Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity
058 – Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
060 (NEAT) – Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG).
Also see article printed in NAM
064 – Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
IMPACT – NHS England PrEP study








POPPY SLEEP  (Sub study of POPPY)


Want to be part of our research?